BMS Touts Breyanzi's Outpatient Administration As EU Approval Beckons
The US major won a positive opinion from the EU CHMP for Breyanzi with hopes the advantage of outpatient administration could help combat the lack of market impetus for CAR-T therapies.
You may also be interested in...
The company has maintained faith in autologous CAR-Ts, and its latest data show early signs of strong efficacy and favorable tolerability, possibly enabling outpatient use.
Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.
Several new drugs are now on track for an EU marketing authorization after getting the EMA’s thumbs up this week.